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THE FDA V. JOE CAMEL: AN ANALYSIS OF THE
FDA'S ATTEMPT TO REGULATE TOBACCO AND
TOBACCO PRODUCTS UNDER THE FEDERAL
FOOD, DRUG AND COSMETIC ACT
I. INTRODUCTION
The term "drug" means ... articles (other than food) intended to affect the struc-
ture or any function of the body of man.'
The term "device" . . . means instruments, apparatus, and contrivances, including
their components, parts, and accessories, intended... to affect the structure or any
function of the body of man.!
These two provisions from the Federal Food, Drug, and Cosmetic Act (FDCA)
define the jurisdiction that Congress has granted the Food and Drug Administration
(FDA) to regulate drugs and drug delivery devices. Since the creation of the Food and
Drug Administration in 1938, these provisions have not been interpreted by the FDA
to include tobacco or tobacco products.
However, on August 9, 1995, David Kessler, Commissioner of Food and Drugs,
reversed sixty years of FDA policy and released a Proposed Rule entitled "Regulations
Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco Products to
Protect Children and Adolescents,"3 seeking to establish regulatory jurisdiction over
tobacco and tobacco products. This proposal, citing FDA findings that nicotine is a
body-altering drug and that tobacco products are drug delivery devices, declares that
the FDA has jurisdiction over tobacco and tobacco products pursuant to the FDCA.
Although the FDA has entitled this proposal a child and adolescent protection plan,
there is no question that the issue at stake here is the FDA's attempt to establish for
itself regulatory jurisdiction over tobacco and tobacco products.
This proposal has sent shockwaves throughout Southern States dependant upon
the tobacco industry as well as the halls of Congress. The response has been both swift
and extensive. In the two months following Commissioner Kessler's action, five bills
were introduced in the Congress challenging the Proposed Rule4 and lawsuits seeking
declaratory and injunctive relief against Kessler and the FDA have been filed by tobac-
co companies, advertisers, convenience store operators, and tobacco farmers.
This Note will examine the history of tobacco regulation from the passage of the
Pure Food and Drug Act in 1906 through the issuance of the Proposed Rule by the
FDA, analyze the Proposed Rule, discuss the challenges, both legislative and legal, to
the Proposed Rule, and offer an analysis regarding the battle over the jurisdiction of
1. 21 U.S.C. § 321(g)(2) (1994).
2. 21 U.S.C. § 321(h)(2) (1994).
3. 60 Fed. Reg. 41,314 (1995) (to be codified at 21 C.F.R. §§ 801, 803, 804, and 897).
4. See Section IV.
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tobacco regulation.
H. THE HISTORY OF TOBACCO REGULATION
The history of Federal involvement in the regulation of tobacco and tobacco
products began in 1914 with the pronouncement that tobacco not labelled for medicinal
use was not subject to regulation by the predecessor of the FDA. Since then there have
been numerous attempts, both legislative and legal, to place tobacco within the juris-
diction of the FDA. All of these attempts have failed due to Congress' clear intent that
tobacco not be regulated as a drug or drug delivery device under FDA jurisdiction.
The debate over Federal regulation of tobacco was first addressed in 1914, when
the FDA's predecessor (the Bureau of Chemistry in the Department of Agriculture)
announced that only tobacco which had been labeled for a medicinal purpose was sub-
ject to the scope of the Pure Food and Drugs Act of 1906' and that "tobacco and its
preparations which are not so labeled and are used for smoking or chewing or as snuff,
and not for medicinal purposes are not subject to the provisions of the act." This lack
of jurisdiction was addressed in 1929, when legislation was introduced intending to
place tobacco within the regulatory jurisdiction of the Bureau of Chemistry, which
enforced the nation's drug laws.' Again, noting that the Bureau of Chemistry had no
jurisdiction over tobacco which was not labelled as medicinal, Congress did not pass
this bill.
The Bureau of Chemistry was replaced as the Federal regulator of drugs in 1938
when the Federal Food, Drug, and Cosmetic Act was enacted, creating the FDA.
Under the FDCA, the FDA was granted jurisdiction over any drugs intended to affect
the structure or any function of the body,' as well as any device which was intended
to deliver such a drug into the body.9 At that time, repeating the stance of its prede-
cessor, the FDA announced that it had no jurisdiction under the FDCA over any tobac-
co product as a drug absent a claim that it was being sold for a medicinal purpose by
the manufacturer. This position was reiterated several times between 1940 and 1952."
In 1956, a bill was introduced to amend the FDCA to grant FDA regulatory
authority over cigarettes." This bill did not pass. Similarly, in 1963, bills were intro-
duced in both the House and the Senate to place all smoking products under the au-
thority of the FDA. 2 The sponsor of the House bill acknowledged that the reason for
the bill was that "smoking products do not come under the protection of the FDA."'3
Like all previous attempts, neither of these bills passed.
In 1964, the Surgeon General issued a report which outlined the risks associated
with smoking and tobacco use. In response to the report, legislation was again intro-
duced to grant the FDA the authority to regulate tobacco and cigarettes. 4 At this time
5. Pub. L. No. 59-384, 34 Stat. 763 (1906).
6. Service and Regulatory Announcements, No. 13 (1914).
7. S. 1468, 71st Cong., 1st Sess. (1929).
8. 21 U.S.C. § 321(g)(2) (1994).
9. 21 U.S.C. § 321(h)(2) (1994).
10. Action on Smoking and Health (ASH) v. Harris, 655 F.2d 236 (D.C. Cir. 1980).
11. H.R. 11280, 84th Cong., 2nd Sess. (1956).
12. H.R. 5973, 88th Cong., 1st Sess. (1963); S. 1682, 88th Cong., Ist Sess. (1963).
13. 109 Cong. Rec. 10316 (June 6, 1963).
14. H.R. 2248, 89th Cong., Ist Sess. (1965).
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officers from both the Department of Health, Education, and Welfare (HEW) and the
FDA testified in hearings before the House Committee on Interstate and Foreign Com-
merce that the FDA had no jurisdiction to regulate tobacco under the FDCA without a
claim of medicinal purpose."
Ultimately, rather than granting the authority to regulate tobacco to the FDA,
Congress enacted the Federal Cigarette Labeling and Advertising Act of 1965
(FCLAA)16 in order to establish a comprehensive Federal program to deal with label-
ing and advertising with respect to any relationship between smoking and health. In the
thirty years since the enactment of the FCLAA, several attempts to place tobacco
under the regulatory authority of the FDA have been introduced in Congress. None of
these have passed, and the FDA has not legislatively been granted jurisdiction over
tobacco and tobacco products.
In 1972 Congressional hearings, FDA Commissioner Charles Edwards reaffirmed
that the FDA did not have jurisdiction over tobacco, stating that "the regulation of
cigarettes is to be the domain of Congress ... [and] labeling or banning cigarettes is a
step that can be taken only by the Congress. Any such move by the FDA would be
inconsistent with the clear congressional intent."' 7 At this time, the FDA also rejected
a plan by the General Counsel of HEW, Wilmont Hastings, to initiate a test case in
order to determine whether the FDA had jurisdiction over cigarettes."
In 1976, Congress enacted the Toxic Substances Control Act (TSCA), empower-
ing the EPA to regulate substances that might pose a threat to health. 9 The TSCA's
definition of chemical substance included an exception for "tobacco or any tobacco
product."2 Also in 1976, following a district court ruling which granted the Consum-
er Product .Safety Commission jurisdiction to consider a petition to regulate cigarettes
under the Federal Hazardous Substances Act (FHSA), Congress amended the FHSA to
exclude tobacco and tobacco products from its definition of a hazardous substance."
In doing so, Congress stated that:
the clear mandate of Congress is that the basic regulation of tobacco and tobacco
products is governed by the legislation dealing with the subject, the Cigarette La-
beling and Advertising Act of 1969, and that any further regulation in this sensitive
and complex area must be reserved for specific Congressional action.22
Although Congress clearly stated its intent that it alone be the sole Federal regu-
lator of tobacco and tobacco products at these hearings, they were not the end of the
debate over expansion of FDA jurisdiction to include tobacco. Between 1977 and
1979, five bills were introduced into Congress (four in the House, one in the Senate)
intending to grant jurisdiction to the FDA; all failed.23
15. Hearings before the House Comm. On Interstate and Foreign Commerce on HA. 2248, 89th
Cong., 1st Sess. 193 (1965).
16. 15 U.S.C. §§ 1331-1341 (1994).
17. Hearings Before the Consumer Subcomm. of the Senate Comm. on Commerce on S. 1454,
92nd Cong., 2d Sess. (1972) (testimony of FDA Commissioner Charles Edwards).
18. Public Health Cigarette Amendments of 1971: Hearings Before the Consumer Subcomm. of the
Senate Committee on Commerce, 92d Cong., 2d Sess. 239, at 245-46 (1972).
19. 15 U.S.C. §§ 2601-2629 (1994).
20. 15 U.S.C. § 2602(2)(B)(iii) (1994).
21. Consumer Product Safety Commission Improvements Act, Pub. L. No. 94-284, 90 Stat. 503
(1976) (codified as amended at 15 U.S.C. § 1261(0(2) (1994).
22. S. Rep. No. 251, 94th Cong., 2nd Sess. 43 (1976).
23. H.R. 2419, 95th Cong., 1st Sess. (1977); H.R. 3879, 95th Cong., 1st Sess. (1977); H.R. 7168,
1996]
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Through 1976, all major attempts to place tobacco within the regulatory reach of
the FDA had come from Congress itself. Private initiative to do so was first attempted
in 1977, when a citizen's watchdog group, Action on Smoking and Health (ASH),
along with thirteen other organizations, filed a petition with the FDA requesting that it
assert jurisdiction over tobacco. When the Commissioner of Food and Drugs, Donald
Kennedy, rejected the petition, ASH filed suit in order to challenge that decision. 4
The chief issue in this case was ASH's contention that tobacco manufacturers were
selling cigarettes with the sole intention of delivering a body altering drug (nicotine),
therefore placing them within the regulatory jurisdiction of the FDA. The Circuit
Court, affirmed the lower court's holding that ASH did not, and could not, establish
the near exclusivity of consumer use of cigarettes with the intent to affect the structure
or any function of the body of man. In holding that tobacco did not fall within the
regulatory jurisdiction of the FDA, the Circuit Court stated that any expansion of the
FDCA is the job of Congress.
However, ASH was not alone in being concerned with the hazards of tobacco
use. In fact, research and medical studies which have been released in the last two
decades have left no doubt about the dangers of tobacco and tobacco products use.
These dangers include increased rates of cancer, heart attacks, and birth defects among
users. In response to these studies, as well as public awareness of these dangers, ef-
forts to place tobacco within the jurisdictional authority of the FDA have been stepped
up in recent years.
Since ASH, tobacco regulation has been addressed by Congress almost annually;
however, there has been nothing to indicate any change in Congress' approach towards
FDA regulation of tobacco and tobacco products. In 1984, the House Committee on
Energy and Commerce stated that "Federal laws that protect the public from hazardous
food, drugs, and consumer products do not apply to cigarettes."" This declaration
once again reaffirmed Congress' stance that tobacco and tobacco products do not fall
within the regulatory reach of the FDA.
In 1986, Congress, addressing the separate regulatory need for smokeless tobacco
products, enacted the Comprehensive Smokeless Tobacco Health Education Act
(CSTHEA).26 The CSTHEA was enacted in order to provide a Federal regulatory
scheme in order to regulate the manufacture, packaging, and distribution of smokeless
tobacco products. Significantly, the CSTHEA does not grant any regulatory jurisdiction
to the FDA regarding smokeless tobacco products.
Following the enactment of the CSTHEA, efforts attempting to place tobacco and
tobacco products within the purview of the FDA continued. In 1987, 1989, 1992, and
1993, bills were introduced to create new regulatory categories for tobacco and tobacco
products.27 These categories would have placed tobacco and tobacco products under
95th Cong., 1st Sess. (1977); S. 3317, 95 Cong., 2d Sess. (1978); H.R. 279, 96th Cong., 1st Sess.
(1979).
24. ASH v. Harris, 655 F.2d 236 (D.C. Cir. 1980).
25. H.R. Rep. No. 805, 98th Cong., 2d Sess. 12 (1984).
26. 15 U.S.C. §§ 4401-4408 (1994) (see below, Section II, part A for a full discussion of the
provisions of the CSTHEA).
27. H.R. 3294, 100th Cong., 1st Sess. (1987); H.R. 1494 and S. 769, 101st Cong., 1st Sess.
(1989); H.R. 4350 and S. 2298, 103d Cong., 1st Sess. (1992); H.R. 2147 and S.672, 104th Cong., 1st
Sess. (1993).
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the regulatory umbrella of the FDA. None of these bills were enacted.
As shown by the FDA's consistent refusal since 1938 to regulate nicotine as a
drug, as well as Congress' clear intent that it not be allowed to do so, the release of
Commissioner Kessler's Proposed Rule to expand FDA jurisdiction to include regula-
tion of tobacco and tobacco products is both a complete reversal of its longstanding
policy regarding such regulation and a unilateral move to grant itself jurisdiction where
Congress has not seen fit to do so.
III. PRESENT GOVERNMENT REGULATION
Consistent with the provisions of the Federal Cigarette Labelling Act and Com-
prehensive Smokeless Tobacco Health Education Act, Congress has created a compre-
hensive program to regulate the manufacture, packaging, and distribution of tobacco
and tobacco products. However, the Federal government is not the sole regulator of
tobacco. There are also regulations regarding tobacco and tobacco products in place in
all fifty states. The following is an analysis of the present position of government
regulation of tobacco and tobacco products.
A. Federal Regulation
As evidenced by numerous concessions of anti-tobacco forces, clear Congres-
sional legislative intent, and several findings by Congressional committees, Congress
has reserved for itself the right to regulate tobacco and tobacco products. The bulk of
this regulation exists in two statutes: the Federal Cigarette Labeling and Advertising
Act (FCLAA),2s and the Comprehensive Smokeless Tobacco Health Education Act
(CSTHEA).
29
The FCLAA was enacted in 1965 in order to establish a "comprehensive federal
program to deal with cigarette labeling and advertising with respect to any relationship
between smoking and health."'" Among its provisions which regulate the manufacture,
packaging, and distribution of cigarettes, the FCLAA grants the Federal Trade Com-
mission (FTC) the authority to administer the implementation and administration of the
programs by which all packs of cigarettes sold or distributed, as well as all advertise-
ments for cigarettes, within the United States must carry one of four Congressionally
mandated warning labels." The Act also grants the Department of Health and Human
Services (HHS) the authority to review lists of ingredients added to tobacco in ciga-
rettes and to report to Congress on any perceived health effects of those added ingredi-
ents.32 Finally, the Secretary of HHS is authorized to transmit an annual report to
Congress concerning current information about the health consequences of smoking
and recommendations for legislation."
In 1986, Congress enacted the Comprehensive Smokeless Tobacco Health Educa-
tion Act, in order to establish and carry out a program to inform the public of any
dangers to human health resulting from the use of smokeless tobacco products. 4
28. 15 U.S.C. §§ 1331-1341 (1994).
29. 15 U.S.C. §§ 4401-4408 (1994).
30. Federal Cigarette Labeling and Advertising Act, Pub. L. No. 89-92, § 2, 79 Stat. 282 (1965)
(codified as amended at 15 U.S.C. § 1331 (1994)).
31. 15 U.S.C. §§ 1333(a)(1), 1333(c) (1994).
32. 15 U.S.C. § 1335(a) (1994).
33. 15 U.S.C. § 1337(a) (1994).
34. Pub. L. No. 99-252, § 2, 100 Stat. 30 (1986) (codified at 15 U.S.C. § 4401(a)(1) (1994)).
1996]
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Among its provisions regulating smokeless tobacco products, the CSTHEA grants the
Secretary of HHS the authority to develop and distribute educational programs,
materials and public service announcements concerning the dangers of smokeless to-
bacco, including making grants available to the states to assist in the distribution of
such information.35 The Act also prohibits the manufacture, packaging, or distribution
of any smokeless tobacco product without one of four warning labels, 6 and requires
all manufacturers, packagers, and importers of smokeless tobacco to provide the Secre-
tary of HHS a list of all ingredients used in the manufacture of that product, as well as
the quantity of nicotine contained in that product.37
Further, the Act requires the Secretary of HHS to report biennially to Congress a
summary of health research on smokeless tobacco, as well as information regarding
any ingredients used in the manufacture of smokeless tobacco which poses a health
risk, and any recommendations for legislation and administrative action.3" Finally, the
Act requires the FTC to report biennially to the Congress the state of sales, advertis-
ing, and marketing practices associated with smokeless tobacco, with any recommenda-
tions for legislation and administrative action.
There are several other agencies within the federal government which have regu-
latory interests in tobacco and tobacco products. Among the agencies which have mi-
nor regulatory interests are the Bureau of Alcohol, Tobacco and Firearms,39 the Secre-
taiy of Health and Human Services," the Department of Agriculture,4' and the Inter-
nal Revenue Service.42
Together, the regulations contained in the FCLAA, the CSTHEA, as well as the
minor regulatory interests of other governmental agencies, provide an extensive regula-
tory scheme which Congress has implemented and now uses to regulate tobacco and
tobacco products.
B. State Regulation
The federal government is not the only regulator of tobacco and tobacco prod-
ucts. There is currently regulation of these products in all fifty states. Major areas that
have been regulated by state governments include restrictions on tobacco and tobacco
products use by minors,43 licensing requirements," and restrictions on vending ma-
35. 15 U.S.C. § 4401 (1994).
36. 15 U.S.C. § 4402(a) (1994).
37. 15 U.S.C. § 4403 (1994).
38. 15 U.S.C. §§ 4403(b), 4407(a) (1994).
39. ATF has authority to collect excise taxes on tobacco products, to regulate manufacture of
tobacco products, and to qualify and regulate manufacture of tobacco products. 27 C.F.R. § 270.1
(1994).
40. The Secretary has authority to transmit to Congress every three years a report describing
current research findings made with respect to the addictive property of tobacco and to recommend
legislation and administrative action deemed appropriate. 42 U.S.C. § 290aa-2 (1988).
41. The Department of Agriculture has the authority to set production quotas and price levels for
tobacco leaf. Agricultural Adjustment Act of 1938, 7 U.S.C. § 1281 (1994).
42. The IRS has the authority to implement tax collection for the sale of cigarettes, Internal Reve-
nue Code, 26 U.S.C. § 5701(b) (1994).
43. These regulations include a minimum age of purchase (19 in 3 states, 18 in 47 states), the
prohibition of the purchase or use by minors of tobacco or tobacco products (in 32 states), and the
prohibition of possession of tobacco or tobacco products by minors (in 17 states). The Tobacco Insti-
tute, State Tobacco Sales Restriction Laws (September, 1995) (unpublished material on file with Jour-
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chine and loose cigarette sales."5 Thus, several areas of regulation covered by the
FDA's Proposed Rule have been addressed by state governments for years.
C. Summary of Present Government Regulation of Tobacco
As required by the FCLAA, and reflective of Congress' clearly expressed intent
that it be the sole federal regulator of tobacco and tobacco products, a comprehensive
federal program has been implemented by Congress to regulate tobacco and tobacco
products. This program includes regulation by the FDCA, FCLAA, CSTHEA, as well
as several other Government Agencies. Further, this federal program has been supple-
mented by further regulation in all fifty states. Taken together, these federal and state
schemes adequately regulate the manufacture, packaging, marketing, distribution, and
sales of tobacco and tobacco products. Further, these schemes can be expanded, allow-
ing further regulatory measures to be enacted without creating new regulatory cate-
gories or the requiring the expansion of any enabling legislation, thereby drastically re-
ducing the need for the FDA's Proposed Rule.
IV. THE FDA'S PROPOSED RULE
On August 9, 1995, FDA Commissioner David Kessler, released a Proposed
Rule entitled "Regulations Restricting the Sale and Distribution of Cigarettes and Smo-
keless Tobacco Products to Protect Children and Adolescents."' The regulatory ob-
jectives of the Proposed Rule are as follows:
[To] reduce the many avenues of easy access to tobacco products available to chil-
dren and teenagers, and to make it harder for young people to buy these prod-
ucts.... reduce the powerful and alluring imagery used in tobacco advertising and
promotion that tends to encourage impressionable young people to initiate tobacco
use.... enhance the positive image of a smoke-free generation .... and educate
people about the specific and relevant health risks associated with tobacco use and
to disseminate information about quitting.47
Upon issuing this Proposed Rule, Commissioner Kessler also released an analysis
of agency jurisdiction over tobacco and tobacco products. This section will analyze
both the FDA's claim of jurisdiction and the Proposed Rule itself, highlighting its
important regulatory elements.
nal).
44. These regulations include the requirement of a retailer license (in 35 states), requirement that
a license, law or sign be posted (in 35 states), provisions for unannounced inspections by state offi-
cials (in 19 states), and allowance for the suspension or revocation of a retailer license for violations
of state regulatory codes (in 16 states). Id.
45. These regulations include mandating retailer supervision of vending machines (in 17 states),
restrictions regarding the location of vending machines (in 17 states), as well as the prohibition of
loose sales of cigarettes (in 19 states). Id.
46. 60 Fed. Reg. 41,314 (1995) (to be codified at 21 C.F.R. pts. 801, 803, 804, and 897) (pro-
posed August 11, 1995).
47. U.S. Food and Drug Administration, DEPARTMENT OF HEALTH AND HuMAN SERVICES, Nico-
tine In Cigarettes and Smokeless Tobacco Products is a Drug and These Products are Nicotine Deliv-
ery Devices Under the Federal Food, Drug, and Cosmetic Act, 60 Fed. Reg. 41,454, 41,787 (1995).
19961
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A. The Jurisdictional Claim
Along with the release of the Proposed Rule, the FDA issued an analysis of its
jurisdiction over tobacco and tobacco products: Nicotine In Cigarettes and Smokeless
Tobacco Products Is a Drug and These Products Are Nicotine Delivery Devices Under
The Federal Food, Drug, and Cosmetic Act.' Citing extensive investigation and anal-
ysis, the FDA concluded that cigarettes and smokeless tobacco products "affect the
structure or any function of the body" because they have pharmacological effects and
lead to addiction, 9 and that tobacco manufacturers "intend" that their products have
addictive and significant pharmacological effects.5" Based upon those findings, the
FDA has concluded that nicotine-containing cigarettes and smokeless tobacco products
are drug delivery systems that are appropriately regulated as devices."
B. The Regulations that Make up The Rule
The FDA's Proposed Rule includes three major regulatory components designed
to reduce tobacco and tobacco use by minors. The first consists of regulations that
would govern the advertising and promotion of tobacco and tobacco products, the
labeling of tobacco packaging, and the retail sales of tobacco and tobacco products.
The second outlines the duties and responsibilities of manufacturers, distributors, mar-
keters, and retailers of tobacco and tobacco products. Finally, penalties and sanctions
to be assessed against violators are detailed.
The proposed regulations regarding advertising and promotion of tobacco and
tobacco products include restrictions on outdoor advertising, 2 other forms of advertis-
ing, "restrictions on the use of logos and brand names, 4 a requirement that all ciga-
rette advertisements include the phrase "cigarettes-a nicotine delivery device,"" pro-
hibition of brand-name sponsorships," the distribution of free product samples,-" and
all advertising in any media not specifically enumerated within the Proposed Rule."
The Proposed Rule also grants the FDA broad authority to pursue false or misleading
cigarette advertising."
48. Id. at 41,545.
49. Id. at 41,467.
50. Id. at 41,471.
51. Id. at 41,455.
52. The proposal bans all outdoor advertising within 1,000 feet of any playground, elementary
school or secondary school, including signs on retail stores. Proposed Regulations, supra note 47, at
41,374 (897.30(b)).
53. The proposal limits all other advertising to black text on a white background except for ad-
vertising in certain adult periodicals and requires all cigarette advertising to carry a second warning
statement in addition to the Surgeon General's warning already required. Id. at 41,374 (897.32(a)),
(897.32(c)).
54. The Proposed Rule limits logos and brand names on race cars, driver uniforms, etc, to a
black on white format, and bans both the use of tobacco brand names on any non-tobacco product
and the use on tobacco products of brand names associated with non-tobacco products except those in
use by Jan. 1, 1995. Id. at 41,374 (897.30(a)(2)), (897.34(a)), (897.32), (897.16(a)).
55. Id. at 41,374 (897.32(b)).
56. The Proposed Rule would allow only corporate sponsorships, so long as the tobacco company
was extant on Jan.l, 1995. Id. at 41,374 (897.34(c)).
57. The proposal would ban such distribution either through the mail or in person. Id. at 41,374
(897.16(d)).
58. Id. at 41,374 (897.30(a)).
59. This includes omissions, lack of balance, and lack of substantial evidence. Id. at 41,375
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Proposed regulations regarding the labeling of tobacco and tobacco products
include a requirement that each package display the word "cigarettes" under the brand
name in letters at least half as large as those used in the brand name,' and a ban on
all cigarette labeling in any media not specifically enumerated in the proposed rule.
6'
In addition, several provisions in the Proposed Rule regulate the sale and distribution
of tobacco and tobacco products. These proposed regulations include bans on vending
machine sales,62 self-service displays, 63 sale and distribution by mail,' sales other
than from unopened packages,65 and sale of packages containing fewer than 20 ciga-
rettes.66
The Proposed Rule also provides that every person who furthers the marketing of
cigarettes or smokeless tobacco products will be deemed a distributor-including pre-
sumably, advertising agencies, publishers, and outdoor companies. 67 Every distributor
is responsible for ensuring that the cigarettes or smokeless tobacco products it manu-
factures, labels, advertises, packages, distributes or sells comply with the Proposed
Rule.'
The Proposed Rule would also require tobacco manufacturers to fund a
$150,000,000 per-year national public education campaign to discourage underage
tobacco use, 69 remove from retail outlets all self service displays, advertising, labeling
and other manufacturer-owned items that do not comply with the Proposed Rule,7"
and conduct visual inspections within the normal course of business in order to ensure
that retailers are complying with the Proposed Rule.7' Further, it would require that
every retailer ensure that all sales are direct, face to face transactions.72
Together, these provisions would regulate the packaging, marketing, distribution,
and sales of tobacco and tobacco products. They also call for an annual payment by
tobacco manufacturing companies of $150,000,000 to fund an educational program
designed to discourage underage tobacco use. In addition, the Proposed Rule contains
several provisions outlining penalties and sanctions to be imposed for violations of
these regulations. Failure to comply with any of the restrictions or requirements in the
FDA proposal would result in the misbranding of the cigarette brand(s) involved, a
prohibited act under the FDCA. 73 Such prohibited acts may be enjoined by court act
and punished as misdemeanors without a mens rea requirement.74 Further, misbranded
articles (cigarettes or labeling) may be seized and condemned by the federal govern-
(897.36).
60. Id. at 41,374 (897.24).
61. Id. at 41,374 (897.30(a)).
62. Id. at 41,374 (897.16(c)).
63. Id.
64. Id.
65. Id. at 41,373 (897.14(c)).
66. Id. at 41,374 (897.16(b)).
67. Id. at 41,373 (897.3(c)).
68. Id. at 41,373 (897.10).
69. Id. at 41,374 (897.29).
70. Id. at 41,373 (897.12(a)).
71. Id.
72. Id. at 41,373 (897.14).
73. 21 U.S.C. §§ 321(a)-(c), (k), 502(a),(q), 709.





Civil penalties may be assessed by the FDA for violations of the device provi-
sions of the FDCA in the amount of $15,000 per violation and up to $1,000,000 for all
violations joined in a single proceeding. Also, based upon the criteria for restricted
devices, an argument could be constructed that failure to comply with the FDA-im-
posed restrictions subjects the noncomplying product or labeling to the notification,
replacement-refund, or recall provisions applicable to devices.76
C. Summary of the FDA's Proposed Rule to Regulate Tobacco and Tobacco
Products
The FDA has based its claim that it has jurisdiction over tobacco and tobacco
products upon findings that nicotine is a drug within the definition of the FDCA and
that the tobacco industry intends to distribute nicotine in order to affect the structure or
function of the body. From these findings, the FDA concluded that tobacco and tobac-
co products are drug delivery devices within the definition of the FDCA.
The proposed regulations that make up the Proposed Rule cover the marketing,
packaging, advertising, sales, and distribution of tobacco and tobacco products. Howev-
er, the Proposed Rule is problematic in that several of its regulations are already in
place as preexisting federal or state regulations. Further, several of the provisions are
of dubious constitutionality. Although several of these regulations are already in place
within the regulatory schemes provided by Congress and the state governments, these
proposed regulations would be contained within the Code of Federal Regulations.
Moreover, the Proposed Rule does not call for the repeal of any provisions of the
FDCA, FCLAA, or CSTHEA, and, thus, would create a second federal regulatory
scheme for the regulation of tobacco and tobacco products.
Several other provisions of the Proposed Rule are problematic in that they invoke
constitutional questioning. Packaging and marketing regulations called for by the pro-
posal both compel and restrict language used in marketing and advertising of tobacco
and tobacco products. These include the requirement of a second warning on all tobac-
co packaging and advertising, a prohibition of the use of tobacco product logos and
brand names on non-tobacco products, a prohibition of brand name sponsorships, and a
ban on advertising in several media forms.
Other such regulations include a ban on several varieties of tobacco sales meth-
ods which are not face-to-face, the declaration that any person involved in tobacco
marketing is deemed a distributor of tobacco and tobacco products, and requirement of
an annual $150,000,000 payment to fund an anti-tobacco educational program. Because
of the overlapping nature of several of the proposed regulations, as well as the ques-
tionable constitutionality of several others, the Proposed Rule was challenged immedi-
ately in both the Halls of Congress and the tobacco states of the South.
75. 21 U.S.C. § 304(a) (1994).
76. 21 U.S.C. § 518 (1994).
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V. CHALLENGES TO FDA REGULATION
Following the announcement of the Proposed Rule by Commissioner Kessler,
several challenges to the FDA plan were quickly initiated. These challenges came in
two forms. First, Congressional legislation was introduced in order to pre-empt, or
outright prohibit, the FDA regulations. In addition, lawsuits were filed by the five
largest tobacco manufacturers in the United States, several groups of tobacco farmers,
advertisers, and convenience store owners against the FDA and Commissioner Kessler,
seeking an injunction against the enactment of the proposed rule.
A. House Bills
The first legislative response to the Proposed Rule was from Rep. David B. Fun-
derburk of North Carolina on September 6, 1995. Funderburk's bill, entitled the Motor
Sports Protection Act,77 prohibits any regulation of tobacco or tobacco product adver-
tising or use at any NASCAR event, or other sporting event, by the Secretary of HHS
or any other Federal official under the FDCA, FCLAA, or CSTHEA. The bill has been
co-sponsored by fifty representatives (14 democrats, 36 Republicans)8 and has been
referred to the House Commerce Committee.
One day later, on September 7, 1995, a second bill, the Tobacco Farmer Protec-
tion Act,7 9 was introduced onto the House floor by Rep. L.F. Payne (D-VA). This
bill, co-sponsored by twenty-two representatives (11 democrats, 11 Republicans),'
prohibits the Secretary of Health and Human services from regulating the sale or use
of tobacco products under the FDCA, FCLAA, or CSTHEA.8 Payne's bill repeals
any regulations issued by the Secretary of HHS enacted prior to passage of the bill and
declares that the Secretary of HHS has no authority to regulate the sale or use of to-
bacco or tobacco products.
On September 28, 1995, Rep. Scotty Baesler (D-KY) introduced the Youth
Smoking Prevention Act of 199582 which has since gained three co-sponsors.13 This
bill is pre-emptive in nature, implementing federal regulation over tobacco, while de-
nying the FDA any jurisdiction over tobacco and tobacco products. The Youth Smok-
ing Prevention Act has regulations regarding the sale and distribution of tobacco and
tobacco products to minors 4 and the sale and distribution of tobacco and tobacco
77. H.R. 2265, 104th Cong., 1st Sess. (1995).
78. Bass (R-NH), Beasler (D-KY), Ballenger (R-NC), Barr (R-GA), Boehner (R-OH), Browder (D-
AL), Bryant (R-TN), Bunning (R-KY), Burr (R-NC), Burton (R-IN), Callahan (R-AL), Chambliss (R-
GA), Chrysler (R-MI), Clayton (D-NC), Coble (R-NY), Collins (R-GA), Cramer (D-AL), DeLay (R-
TX), Goodlatte (R-VA), Gordon (D-TN), Graham (R-SC), Hefner (D-NC), Hancock (R-MO), Heineman
(R-NC), Hilleary (R-TN), Hostettler (R-NC), Jones (R-NC), Kingston (R-GA), Lewis (R-KY), McIntosh
(R-IN), Mica (R-FL), Myrick (R-NC), Norwood (R-GA), Parker (D-MS), Payne, Jr. (D-VA), Peterson
(D-FL), Quillen (R-TN), Roberts (R-KY), Rogers (R-KY), Rose (D-NC), Scarborough (R-FL), Scott (D-
VA), Sisisky (D-VA), Stump (R-AZ), Souder (R-IN), Tanner (D-TN), Taylor (R-NC), Ward (D-KY),
Watts (R-OK), and Zeliff (R-NH). Id.
79. Although the bill has been referred to as the Tobacco Farmer Protection Act, this has not
been officially adopted as the short title. Id.
80. Ballenger (R-NC), Beasler (D-KY), Boucher (D-VA), Bunning (R-KY), Chambliss (R-GA),
Clybum (D-SC), Clement (D-TN), Coble (R-NC), Funderburk (R-NC), Gordon (D-TN), Hefner (D-NC),
Jones (R-NC), Peterson (D-FL), Rogers (R-KY), Rose (D-NC), Scott (D-VA), Spratt (D-SC), Taylor
(R-NC), and Ward (D-KY). Id.
81. H.R. 2238(1)(a), 104th Cong., 1st Sess. (1995).
82. H.R. 2414, 104th Cong., 1st Sess. (1995).
83. Hamilton (D-IN), Ward (D-KY), and Rose (D-NC). Id.
84. The bill prohibits the sale of tobacco or tobacco products to minors, prohibits minors from
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products generally.85 It also has several licensing requirements 6 and regulations re-
garding the advertising of tobacco and tobacco products.87 Finally, it requires the Sec-
retary of HHS to make an annual report to Congress on the actions taken by states
pursuant to the bill.
Although .the legislation introduced by Reps. Funderburk and Payne intends
merely to prohibit enforcement of the Proposed Rule released by Commissioner
Kessler, while Rep. Baesler's bill intends to enact a regulatory scheme similar to the
FDA's proposal, all three express the same purpose: the prohibition of FDA regulation
of tobacco and tobacco products. In fact, Both Rep. Payne and Rep. Baesler have
included provisions in their bills which expressly deny the FDA any jurisdictional au-
thority over tobacco and tobacco products.
B. Senate Bills
The first response to Commissioner Kessler's announcement from the Senate
came on September 16, 1995, when Senator Wendell Ford (D-KY) introduced the
Tobacco Products Control Act of 1995.88 Much like Rep. Baesler's House bill, the
Tobacco Products Control Act seeks to regulate tobacco through Congress, while deny-
ing any jurisdictional authority to the FDA. Senator Ford's bill, which has no co-spon-
sors and has been referred to the Senate Commerce Committee, seeks to establish lim-
its on advertising and to provide for increased enforcement of existing state regulations
on advertising for tobacco and tobacco products. 9 It also includes provisions which
would prohibit vending machine sales' and distribution of tobacco or tobacco pro-
ducts without charge. 9'
On September 29, 1995, Senator Jesse Helms (R-NC) introduced The
Motorsports Protection Act,92 attacking the Proposed Rule. This bill, which has three
buying tobacco or tobacco products or presenting false identification for the purpose of buying tobacco
or tobacco products, prohibits the distribution of free samples of tobacco or tobacco products to mi-
nors, and prohibits the distribution of tobacco or tobacco products through the mail to minors. Id. at §
3.
85. The bill prohibits sales of cigarettes in packs of less than twenty, vending machine sales un-
less the vending machine is in plain view and under direct supervision and control of the retailer, and
requires that all sales of tobacco and tobacco products be face to face sales. Id.
86. The bill requires retailers of tobacco or tobacco products to be licensed with their state and
requires states to conduct random unannounced inspections. Id.
87. The bill prohibits any billboard advertising within the line of sight of a school or playground,
and prohibits brand names or logos from being placed on any non-tobacco product marketed specifical-
ly to minors, including toys and video games. Id.
88. S. 1262, 104th Cong., 1st Sess. (1995).
89. Ford's bill amends the FCLAA to prohibit billboard advertising within 500 feet of schools
unless the billboard is adjacent to an interstate and faces away from the school, or is attached to
buildings which sell tobacco or tobacco products, prohibits advertising in magazines which have 15%
or more minor readership, prohibits payments made to motion pictures for the placement of tobacco or
tobacco products as a prop in any motion picture produced for viewing by the general public, and
prohibits the use of brand names or logos in any video game or family amusement center. Id. at § 2.
90. Unless the vending machine is located at a private club, bar or bar area of a food service
establishment, place of employment where the workforce is not significantly made up of minors, or
allowable by state law. Id. at § 4.
91. Unless the tobacco or tobacco product is distributed through coupons allowed by section 7 of
the FCLAA, where individuals can demonstrate they are at least 18, in locations that can be separately
segregates to deny access to minors, or where state law permits. Id.
92. S. 1295, 104th Cong., 1st Sess. (1995).
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co-sponsors,93 denies the FDA any authority to regulate, in any manner, tobacco or
tobacco products.94 It also prohibits the regulation of any use or promotion of tobacco
or tobacco product by any NASCAR participant or agent. This prohibition applies to
any enforcement by the FDA under the FDCA, FCLAA, CSTHEA, as well as any Ex-
ecutive order issued by the President.95
Both pieces of legislation introduced by Senators Ford and Helms have provi-
sions which expressly deny any jurisdiction over tobacco and tobacco products to the
FDA and have been referred to the Senate Commerce Committee. However, these are
two fundamentally different bills. While Senator Helms' bill intends merely to prohibit
enforcement of any FDA regulation of tobacco and tobacco products, Senator Ford's
bill is an attempt to preemptively enact a regulatory scheme similar to the FDA plan.
C. The Courts
On September 7, 1995, five major tobacco companies filed suit against the FDA
and Commissioner Kessler in the United States District Court for the Middle District
of North Carolina seeking to' enjoin the FDA from implementing its Proposed Rule.'
This suit, Coyne Beahm, Inc., et al. v. FDA, et al.,97 attacks the FDA's Proposed Rule
on two fronts. First, it claims that the FDA is denied any jurisdiction over tobacco and
tobacco products by its enabling legislation, the FDCA, the Administrative Procedure
Act, the FCLAA, and the CSTHEA. Second, it challenges the Constitutionality of
several of the regulations which comprise the Proposed Rule.
In their complaint, the tobacco companies claim that any attempt by the FDA to
expand its jurisdiction to include tobacco and tobacco products violates the FDA's
enabling legislation. Specifically, the complaint alleges that the FDA's proposal to
regulate nicotine as a drug, and tobacco and tobacco products as drug delivery devices,
violates Congress' clearly expressed intent that it be the sole federal regulator of to-
bacco and tobacco products.9" It further alleges that the FDA is precluded from such
regulatory jurisdiction by the FDCA, FCLAA, and the CSTHEA. 9 The tobacco com-
panies also contend that the FDA's assertion of jurisdiction relies upon materials not in
the public record and thereby deprives them of their fundamental right to private and
meaningful comment, which violates both the Administrative Procedure Act and the
Fifth Amendment." °
The cigarette companies have also attacked the constitutionality of several of the
regulations not contained within the existing federal or state regulatory schemes.' 1
The companies contend that several of these proposed regulations violate Articles I and
II of the Constitution. The suit claims that the requirement that the tobacco companies
fund a mandated $150,000,000 per year anti-smoking educational campaign is an exer-
93. Faircloth (R-NC), Warner (R-VA), and Thompson (R-TN). Id.
94. S. 1295, 104th Cong., 1st Sess., § 3 (1995).
95. Id. at § 1.
96. Similar suits have since been filed by tobacco farmers, advertisers, and convenience store op-
erators.
97. Plaintiffs' First Amended Complaint at 94, Coyne Beahm, Inc, et al. v. FDA, et al., No.
2:95CV00591 (M.D.N.C. filed Sept. 7, 1995).
98. Id. at 94.
99. Id. at 69-77. For an analysis of the legislative history and Congress' intent regarding the reg-
ulation of tobacco and tobacco product, see discussion supra section I.
100. Id. at 82.
101. For a discussion of these controversial provisions see supra, section 3, part C.
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cise of executive power not authorized by Article II of the Constitution or by valid act
of Congress.0 2 In addition, the suit asserts that this requirement violates the separa-
tion of powers prescribed in the Constitution: 3 it constitutes a tax not enacted by
Congress in violation of Article I, §§ 7, 8. 04
The tobacco companies also claim that the Proposed Rule would violate the pro-
vision of Article I, § 9, which mandates only Congress to appropriate money.' 5 Fur-
ther, the complaint contends that the regulations violate Article II's provision against
conscripting private persons for law enforcement, and Article I, § 8, cl. 3 by exceeding
the Federal government's power under the Commerce Clause by establishing a national
minimum sales age."° Finally the complaint alleges that the FDA's plan violates the
First,'0 7 Fourth,' Fifth,' °9 Eighth," Ninth,"' and Tenth Amendments to the
Constitution.' 2
On October 4, 1995, the tobacco companies filed a Motion for Summary
Judgment, "' asking the District Court to enjoin any regulatory action by the FDA. At
the same time, the FDA filed a Motion to Dismiss,' 4 seeking to have the tobacco
companies' suit dismissed on the grounds that there is no case or controversy until
final regulatory action is taken. At this time, it is probable that the District Court will
deny both of these motions and schedule the suit to be heard on its merits sometime in
early 1996.
D. Summary
At this time, it appears that none of the legislative challenges to Commissioner
Kessler and the FDA will be successful. All of the bills that have been introduced in
the House have been referred to the Commerce Committee, where Committee Chair-
man Thomas Bliley (R-VA) likely will not allow any tobacco legislation to get through
102. Id. at 109(a).
103. Id.
104. Id. at 109(b).
105. Id. at 109(c).
106. Id. at 110, 111.
107. These violations include both compelling and restricting the tobacco companies' speech in
connection with cigarettes, restricting the tobacco's use of certain trademarks and copyrights without
statutory authority, and requiring burdensome reporting procedures to the FDA. Id. at 113-14, 119.
108. The Fourth Amendment is violated by the proposal's requiring burdensome reporting proce-
dures to the FDA. Id. at 119.
109. These violations include requiring the tobacco companies to fund an educational fund, prohibit-
ing the tobacco companies from using certain trademarks or copyrights without statutory authority, and
holding cigarette manufacturers liable for the acts of others over whom they have no legal or practical
authority or control through vicarious liability. Id. at 114, 115(a), 116.
110. The Eighth Amendment is violated by the Proposed Rule's plan to hold cigarette manufactur-
ers liable for the acts of others over whom they have no legal or practical authority or control through
vicarious liability. Id. at 116.
111. The Ninth Amendment would be violated by the FDA's assumption of rights and powers
reserved to Congress. Id. at 118.
112. These violations include a requirement that tobacco companies fund an educational program,
which cannot be granted by Congress in that it is not within the powers granted to Congress by the
Constitution, and violates rights and powers reserved to Congress. Id. at 115(b), 118.
113. Plaintiffs' Motion for Summary Judgment, Coyne Beahm, et aLv. FDA, et al. Case No.
2:95CV00591 (M.D.N.C. filed Oct. 4, 1995).
114. Defendants' Motion to Dismiss, Coyne Beahm, et al. v. FDA, et aL, Case No. 2:95CV00591
(M.D.N.C. filed Oct. 6, 1995).
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the committee to the House floor due to the controversial nature of tobacco regulation.
This will effectively kill any chance of House legislative opposition to the Proposed
Rule.
On the Senate side, it seems unlikely that either the Helms or the Ford bill will
make it out of the Senate Commerce Committee. There has been no action taken on
Senator Ford's bill, which has been met with stern disapproval from several Southern
Republican Senators, including Helms. These Southern Senators will not support any
further regulation of tobacco and tobacco products, neither from the FDA nor from
Congress. To date, the only action that has been taken on the Helms bill has been its
placement on the Senate Calendar for discussion.
Therefore, it appears that the fate of the FDA's Proposed Rule will be decided in
the Courtroom. As mentioned above, the court is likely to dismiss both the FDA's
motion to dismiss and the tobacco companies' motion for summary judgment, placing
the trial on the merits sometime early in 1996. It is also likely that the other court
cases will proceed on roughly the same schedule.
In considering these cases, the courts will apply the test set out by the Supreme
Court in Chevron, U.S.A., Inc. v. Natural Resources Defense Council."' In Chevron,
the Supreme Court held that lower courts must weigh the typical deference given to
regulatory agencies in attempting to expand or define their own jurisdiction against the
typical deference given to clear congressional intent in restricting the jurisdiction of
regulatory agencies. The issue in the present case will likely center on the clarity of
Congress' intent.
It is clear that many attempts to legislatively grant such jurisdiction to the FDA
have been rejected. Although such an argument from silence is likely to be problematic
in court, as the failure of these bills may have resulted from any number of factors
completely independent from the issue of tobacco regulation, it seems probable that a
court would find clear Congressional intent from this history. The comments made by
Representatives, Senators, and other governmental officials at Congressional hearings
will also be considered. Although these factors are not dispositive of Congressional
intent, they are likely to be considered strong indicators of such. Taken together, the
combination of legislative history and testimony before Congressional hearing suggest
that the district court will rule that Congress, and Congress alone, be the sole Federal
regulator of tobacco and tobacco products.
VI. ANALYSIS AND CONCLUSION
This Note has examined the legislative history of the FDA's enabling legislation,
the FDCA, as well as other legislation which Congress has enacted in order to regulate
tobacco and tobacco products, the FCLAA and CSTHEA. This note then concludes
that Congress has shown clear intent that it, and it alone, be the sole regulator of to-
bacco and tobacco products. It has also analyzed the FDA's Proposed Rule, concluding
that it is problematic in two ways. First, it would create a second, overlapping, federal
scheme for the regulation of tobacco and tobacco products. Secondly, several of the
proposal's regulations are of dubious constitutionality.
This Note has also examined the legislative and legal challenges to the FDA




proposal, concluding that any legislative attempt to preempt or prohibit the Proposed
Rule is unlikely to make it through Congress and that the fate of the Proposed Rule
will likely rest in the hands of the Courts.
Based upon the Supreme Court's decision in Chevron, the key issue in any regu-
latory jurisdiction case is going to be the clarity of Congressional intent in restricting
such regulatory jurisdiction. Although there is no definitive statement of such intent
regarding FDA regulation of tobacco and tobacco products, it seems clear that Con-
gress has repeatedly shown such intent throughout the last seventy years.
In addressing this issue, courts are likely to examine the history of Congressional
regulation of tobacco and tobacco products as well as statements made at Congressio-
nal Committee hearings, noting that Congress has consistently denied any regulatory
authority over tobacco and tobacco products to the FDA. Based upon these factors, the
courts are likely to rule that Congress has shown clear intent that it alone be the sole
Federal regulator of tobacco and tobacco products, and deny such regulatory jurisdic-
tion to the FDA.
Barring a settlement between the FDA and tobacco manufacturers, final resolu-
tion of this issue is unlikely to come from the courts any time soon. There is little
doubt that these cases will be appealed and that complete adjudication will take several
years. A more direct resolution to the issue would be a definitive Congressional state-
ment concerning the regulatory jurisdiction of the FDA over tobacco and tobacco
products. If such a statement were to come from Congress, it would likely come in the
form of an FDA reform bill out of the House Commerce Committee, denying such
jurisdiction to the FDA. However, given Congress' reluctance to directly address the
issue of tobacco regulation, such a bill would have a small chance of making its way
through the legislative maze of Congress, leaving the courts as the likely arbiter of this
very sensitive and complex issue.
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